Ensuring populations across the world are vaccinated for COVID-19 is critical to ending the pandemic by increasing immunity, decreasing deaths, and reducing the risk of new variants emerging. The global strategy to reach 70% vaccination coverage by June 2022 requires a coordinated and concerted effort to ensure no one is left behind including the most marginalized and those facing humanitarian crises. Currently however, these populations face the most inequity.

Inequity between countries

Only 458 M have been administered in countries with humanitarian situations.

Low income countries carry the greatest humanitarian caseload, but have received and administered the least vaccines.

Population in Need (PIN) of humanitarian assistance*

<table>
<thead>
<tr>
<th>Country Type</th>
<th>PIN</th>
<th>UMIC</th>
<th>LIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>UMIC (5)</td>
<td>23m</td>
<td>22m</td>
<td>1pm</td>
</tr>
<tr>
<td>LMIC (10)</td>
<td>43m</td>
<td>42m</td>
<td>1pm</td>
</tr>
<tr>
<td>UC (17)</td>
<td>152m</td>
<td>151m</td>
<td>1pm</td>
</tr>
</tbody>
</table>

Inequity within countries

From analysis conducted with countries and partners, marginalized groups or populations of concern in humanitarian settings are at risk of, or are facing further inequity with lower rates of vaccination amongst these populations being seen. These include IDPs, refugees, migrants regardless of status, those living in insecure or non-government controlled areas.

Key Asks

1. Populations of concern must be held in equal regard to the wider population and the principle of contextual parity applied.
2. Leverage humanitarian partners to reach populations of concern.
3. Identify barriers impacting vaccine uptake by populations of concern and develop approaches to address them and ensure gender equity.
4. Ensure adequate microplanning and funding.
5. Ensure sustained funding and planning for RCCE efforts.
6. Monitor inequity within country. Adapt vaccine data tools to collect disaggregated data on administration of vaccines to populations of concern and by gender.
7. Mitigate impact on essential health service delivery and routine immunization services in humanitarian settings.
8. Strengthen the coordination and predictability of arrival of vaccine doses in country, including vaccine type and amount, regardless of the method of procurement.
9. Minimize the procurement or donation of vaccines with short expiry dates.
10. Strengthen COVID-19 vaccine production and distribution in lower middle income (LMIC) and lower income countries (LIC).
11. Manufacturers should waive the requirement for indemnification.
12. Invest in pandemic preparedness and outbreak readiness.
COVID-19 vaccination in humanitarian settings
Advocacy and information brief

Key asks in depth

1. Populations of concern must be held in equal regard to the wider population and the principle of contextual parity applied.
   All stakeholders should work towards achieving the same vaccination coverage amongst populations of concern.

2. Leverage humanitarian partners to reach populations of concern.
   Especially those with existing operational presence providing health services and immunizations:
   National EPI Task Forces should leverage coordination platforms such as the health cluster to support reach
   including at sub-national level;
   - Identify and address any barriers for humanitarian partners to support vaccination roll out; and
   - National partners including national NGOs and civil society organizations have a key role to play in all parts
   of vaccination roll out including supporting a community driven response.

3. Together with communities and partners identify barriers impacting vaccine uptake by populations of concern and develop approaches to address them. This includes ensuring gender equity. Barriers may include:
   - Practice and policies – such as ID requirements, or unclear data protection;
   - Vaccine hesitancy – misinformation, disinformation;
   - Mistrust of authorities or health service providers;
   - Socio cultural norms; and
   - Limited access to vaccination points or availability of vaccines.

4. Ensure adequate microplanning and funding.
   i.e. sub nationally to determine resources, approaches and interventions needed to address specific and additional
   needs of populations of concern
   - Involve populations of concern, such as community leaders, women led community organizations, as well as
   health partners operational in those areas to develop appropriate plans and strategies for vaccination.

5. Ensure sustained funding and planning for RCCE efforts.
   Given the multitude of vaccine types in use, irregularity of vaccine arrival and evolving prioritization strategies to
   modes to deliver vaccination, investments must continue to ensure populations are continually engaged for a
   community driven response.

Additional Resources

**GHC position paper: COVID-19 vaccination in humanitarian settings**
Developed with 28 key partners, agencies and clusters involved in the COVID-19 response, this position paper provides key messages to guide global and country level health cluster partners to advocate and support equitable vaccine availability and uptake for populations of concern in humanitarian settings.

**Risk Communication and Community Engagement guidance on COVID-19 vaccines for marginalised populations**
This inter-agency guidance document aims to supplement the COVAX demand creation package for COVID-19 vaccines with key considerations for humanitarian contexts and marginalised populations with specific access and communication needs.

**The True Cost of Delivering COVID Vaccines: South Sudan**
South Sudan was able to administer stock doses of COVID-19 vaccine through delivery, training, and social mobilization coordinated with several different partners. As new doses arrived in country in August, South Sudan continues to reinforce gaps in the health systems to make vaccinations possible without disrupting existing health services.

See how the Health Cluster is already supporting vaccine response in humanitarian settings. This work was developed by the COVID-19 Vaccination Working Group which is part of the GHC COVID-19 Task Team.